Endovascular Thrombectomy in Patients With Cancer and Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
- 1Department of Surgery, College of Medicine, University of Baghdad, Baghdad, IRQ.
Abstract
Patients with cancer and acute ischemic stroke are underrepresented in randomized thrombectomy trials, and the safety and effectiveness of endovascular thrombectomy (EVT) in this population remain uncertain. We systematically reviewed clinical, procedural, and safety outcomes of EVT in cancer patients compared to non-cancer controls. Searches of PubMed, Scopus, and the Cochrane Library identified 10 observational studies. Meta-analyses summarized outcomes within cancer groups, while comparative analyses calculated risk differences (RDs) as cancer minus control. Bias was assessed using the ROBINS-I (Risk of Bias In Non-randomized Studies of Interventions) tool. Among cancer patients undergoing EVT, the pooled success rate for recanalization was 77.1% (95% CI, 71.2%-83.0%). Symptomatic intracranial hemorrhage (sICH) occurred in 4.5% (95% CI, 2.6%-6.5%). A favorable 90-day functional outcome (modified Rankin Scale (mRS) ≤2) was seen in 26.8% (95% CI, 20.6%-32.9%), with 39.4% (95% CI, 31.6%-47.2%) dying within 90 days. Comparative analyses showed that cancer patients were significantly less likely to attain mRS ≤2 at 90 days (RD, -0.170; 95% CI, -0.223 to -0.116; I² = 23.4%) and had higher 90-day mortality (RD, 0.234; 95% CI, 0.168 to 0.300; I² = 45.1%). No significant differences were found for successful recanalization (RD, -0.033; 95% CI, -0.083 to 0.016; I² = 31.5%) or sICH (RD, -0.001; 95% CI, -0.020 to 0.018; I² = 0%). Sensitivity analyses excluding high-bias studies produced similar results. EVT can yield high recanalization rates with low sICH risk in cancer patients; however, they show poorer functional recovery and higher 90-day mortality than controls. These results emphasize the need for personalized treatment considering both stroke and cancer prognosis.
Related
- Bridging Thrombolysis Versus Direct Endovascular Thrombectomy in Acute Ischemic Stroke Patients With ASPECTS ≤5: A Meta‐Analysis
- Apparent Diffusion Coefficient Composition and Tissue Heterogeneity as Predictors of Functional Outcomes After Endovascular Thrombectomy in Patients With Large Ischemic Core
- Conscious Sedation with Dexmedetomidine or Midazolam during Endovascular Thrombectomy in Acute Ischemic Stroke: Protocol of the Multicenter PEACE Randomized Trial
- Effectiveness of endovascular thrombectomy in large-core ischemic stroke: a real-world cohort study
- Apparent Diffusion Coefficient Fraction Predicts Endovascular Thrombectomy Benefit in Large Ischemic Core
BibTeX
@article{alkhafaji2026endovascular,
title = {{Endovascular Thrombectomy in Patients With Cancer and Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.}},
author = {Nooruldeen H Ali Al-Khafaji and Ali K Al-Shalchy},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116605},
url = {https://europepmc.org/article/MED/42904270},
note = {CC BY},
}
RIS
TY - JOUR
TI - Endovascular Thrombectomy in Patients With Cancer and Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
AU - Nooruldeen H Ali Al-Khafaji
AU - Ali K Al-Shalchy
PY - 2026
DA - 2026/09/20
JO - Cureus
DO - 10.7759/cureus.116605
UR - https://europepmc.org/article/MED/42904270
AB - Patients with cancer and acute ischemic stroke are underrepresented in randomized thrombectomy trials, and the safety and effectiveness of endovascular thrombectomy (EVT) in this population remain uncertain. We systematically reviewed clinical, procedural, and safety outcomes of EVT in cancer patients compared to non-cancer controls. Searches of PubMed, Scopus, and the Cochrane Library identified 10 observational studies. Meta-analyses summarized outcomes within cancer groups, while comparative analyses calculated risk differences (RDs) as cancer minus control. Bias was assessed using the ROBINS-I (Risk of Bias In Non-randomized Studies of Interventions) tool. Among cancer patients undergoing EVT, the pooled success rate for recanalization was 77.1% (95% CI, 71.2%-83.0%). Symptomatic intracranial hemorrhage (sICH) occurred in 4.5% (95% CI, 2.6%-6.5%). A favorable 90-day functional outcome (modified Rankin Scale (mRS) ≤2) was seen in 26.8% (95% CI, 20.6%-32.9%), with 39.4% (95% CI, 31.6%-47.2%) dying within 90 days. Comparative analyses showed that cancer patients were significantly less likely to attain mRS ≤2 at 90 days (RD, -0.170; 95% CI, -0.223 to -0.116; I² = 23.4%) and had higher 90-day mortality (RD, 0.234; 95% CI, 0.168 to 0.300; I² = 45.1%). No significant differences were found for successful recanalization (RD, -0.033; 95% CI, -0.083 to 0.016; I² = 31.5%) or sICH (RD, -0.001; 95% CI, -0.020 to 0.018; I² = 0%). Sensitivity analyses excluding high-bias studies produced similar results. EVT can yield high recanalization rates with low sICH risk in cancer patients; however, they show poorer functional recovery and higher 90-day mortality than controls. These results emphasize the need for personalized treatment considering both stroke and cancer prognosis.
SN - 2168-8184
ER -